Mainz Biomed to unveil breakthrough early cancer detection study results at DDW 2024

FHS
May 11, 2024
12:28 pm

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, will present an analysis from its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in Washington D.C. from May 18th to May 21st. DDW is recognized as a premier forum for the latest advancements in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

Immune checkpoint protein VISTA can directly turn off T-cells during immunotherapy, study finds

A Cleveland Clinic-led team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and

May 17, 2024

Excision’s HIV gene editing clinical trial; Nykode’s $45M placement; Ideaya’s post-ESMO offering

Plus, news from Skye Bioscience, Mediar Therapeutics and Servier. A first look at Excision’s HIV gene editing clinical trial: The company said Wednesday that three

October 26, 2023

The Delisting Risk

You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight

April 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.